微芯生物(688321.SH):擬購買深圳南山智谷產業園B座21層至24層研發及辦公場地
格隆匯 12 月 28日丨微芯生物(688321.SH)公佈,公司擬通過與深圳市大沙河創新產業園建設開發有限公司簽訂《南山智谷產業研發用房定製協議》,擬購買位於廣東省深圳市南山區沙河西路3185號的南山智谷產業園B座21層至24層研發及辦公場地,共計四層,交易金額暫定為235,034,644元人民幣。
此次購買交易完成後,有助於滿足公司研發、經營辦公、營銷等活動的開展,滿足募集資金投資項目實施的需要,促進公司產業的可持續健康發展,對公司未來發展具有重要的戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.